KKR Jan 2025 80.000 call
| Previous Close | 22.12 |
| Open | 22.12 |
| Bid | 22.00 |
| Ask | 22.50 |
| Strike | 80.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 22.12 - 22.12 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 852 |
BloombergKKR Said to Consider $1 Billion Acquisition of Healthium Medtech
(Bloomberg) -- KKR & Co. is considering an acquisition of Indian medical-device maker Healthium Medtech Ltd., according to people familiar with the matter.Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Over StrategyThe private equity firm has been holding talks with Healthium’s owner
BloombergKKR Bets on Domestic Consumption, Private Credit in India Push
(Bloomberg) -- Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s New Chopper Is Demoted After Scorching White House LawnBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsTesla Soars as Musk’s Cheaper EVs Calm Fears Over StrategyBillionaire Pinaults Fight to Pull Gucci Off the Discount RackKKR & Co
- Business Wire
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
STOCKHOLM & LONDON, April 23, 2024--Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
